Hyperlactatemia and in Utero exposure to antiretrovirals: Is the control group the clue?

Pere Soler-Palacín, Andrea Martín-Nalda, Xavier Martínez-Gómez, Susana Melendo, Encarnació Riudor, Jose Antonio Arranz, Maria Espiau, Concepció Figueras

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)


Perinatal antiretroviral (ARV) exposure has been related to hyperlactatemia and lactic acidosis in infants born to HIV-infected mothers. Our objective was to determine the incidence of these conditions during the first year of life in uninfected infants born to HIV-infected mothers and compare the data with infants born to mothers with hepatitis C virus (HCV) infection. We investigated the relationships between hyperlactatemia and neurological and neurodevelopmental disorders by conducting a prospective, comparative cohort study (October 2004 to October 2007) consecutively including children of HIV- and HCV-infected mothers. Liver enzymes, pH, lactic acid, and plasma amino acids were determined at 1.5, 3, 6, and 12 months of life. Pathological hyperlactatemia was defined as lactate >2.1 mmol/liter together with alanine >475 μmol/liter. Seventy-nine patients (39 HIV-exposed patients and 40 unexposed patients) were included. Baseline maternal characteristics in the two groups were similar. Almost 90% of HIV-infected mothers received HAART during gestation, while 10.3% were given AZT monotherapy. Eight newborns received combined therapy and 31 received AZT-based monotherapy. Twelve patients (five exposed and seven nonexposed) had some neurological disorder, and four other patients (one vs. three) showed signs of neurodevelopmental delay, with no significant differences between the groups (p=0.34). Pathological hyperlactatemia was detected in 56.4% (95% CI 39.6-72.2) and 57.5% (95% CI 40.9-73.0) of patients, respectively (p=0.92), and this condition was more frequent in preterm children (p<0.05). ARV use during pregnancy and the neonatal period was not associated with pathological hyperlactatemia. The presence of hyperlactatemia was not associated with neurological or neurodevelopmental disorders. No association was established between the use of ARV agents and the development of hyperlactatemia or neurological disorders in HIV-exposed children during their first year of life. © Copyright 2012, Mary Ann Liebert, Inc. 2012.
Original languageEnglish
Pages (from-to)752-758
JournalAIDS Research and Human Retroviruses
Issue number8
Publication statusPublished - 1 Aug 2012


Dive into the research topics of 'Hyperlactatemia and in Utero exposure to antiretrovirals: Is the control group the clue?'. Together they form a unique fingerprint.

Cite this